2型糖尿病需添加药物治疗患者的管理方法
过去20年2型糖尿病获批药物种类显著增加,部分药物兼具减重、预防主要不良心血管事件(MACE)和保护肾功能等额外获益。本文提出一种实用工具,基于药物降低HbA1c效力及患者HbA1c与个体化目标的距离,为添加药物治疗提供阶梯式指导,并兼顾临床医生与患者偏好。
要点
- 选择添加药物时需了解药物降低HbA1c的效力及患者HbA1c与个体化目标的距离。
- 随糖尿病进展,添加药物降糖疗效存在收益递减,且心脏和肾脏保护获益程度尚未完全明确。
- 本文提出基于药物效力数据的阶梯式实用工具,允许根据医患偏好灵活调整。
核心结论
- 本文旨在为2型糖尿病添加药物治疗提供一种直接的方法,认识到多重用药的局限性以及使用最适合达到治疗目标的药物的重要性。
研究设计与样本
- 本文为方法学文章,提出一种基于现有药物疗效数据的实用工具,提供阶梯式指导。
主要发现
- 过去20年2型糖尿病获批药物及药物类别数量显著增加,可利用互补作用机制的药物应对胰岛素分泌随时间下降所致的进行性高血糖。
- 部分药物提供额外获益,如减重、预防主要不良心血管事件(MACE)和保护肾功能。
- 选择药物时关键要素包括了解所考虑药物降低血红蛋白A1c(HbA1c)的效力及患者HbA1c水平与个体化目标的距离。
- 随糖尿病进展选择药物时需认识到添加药物降糖疗效存在收益递减,且心脏和肾脏保护获益程度尚未完全明确。
- 较新的非胰岛素药物可能分散临床医生对胰岛素这一最有效药物的使用。
临床怎么用
- 本文提出的实用工具利用现有药物疗效数据提供阶梯式指导,并允许根据临床医生和患者偏好灵活调整。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the last 20 years, the number of approved agents and agent classes for management of type 2 diabetes has expanded significantly. This more robust armamentarium affords us the opportunity to utilize drugs with complementary modes of action to address progressive hyperglycemia as insulin secretion declines over time. Furthermore, some of these agents provide additional benefits, such as weight loss, prevention of major adverse cardiac events (MACE), and protection against declining renal function. This dramatic increase of treatment options has led to complex published treatment advice which may be challenging for the busy clinician. A critical element in medication selection is awareness of the hemoglobin A1c (HbA1c)-lowering potency of the agent being considered, and the distance of the patient's HbA1c level from the individualized goal. Other important factors in choosing medication as diabetes progresses include the recognition that there is a diminishing return of glucose-lowering efficacy as add-on agents are introduced, and that the extent of benefit for cardiac and renal protection is not fully understood. In addition, the availability of newer non-insulin agents may distract the clinician from utilizing insulin, the most potent agent available. The goal of this article is to provide a straightforward approach to add-on medication in the treatment of type 2 diabetes, recognizing the limits of polypharmacy and the importance of employing agents best suited to achieving treatment targets. Proposed is a practical tool which provides stepwise guidance, utilizing available data on medication efficacy, while allowing flexibility based on clinician and patient preference.
引用
- Baum HBA. Approach to the Patient With Type 2 Diabetes Requiring Add-On Medication. J Clin Endocrinol Metab. 2024. PMID: 38373247. doi:10.1210/clinem/dgae056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。